Osteologix Holdings (OLGXF) 0.0070 $OLGXF Bone

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2015 at 7:09 PM

Osteologix Holdings (OLGXF) 0.0070 $OLGXF

Bone Metastasis Pipeline Review, H1 2015
M2 - Thu Jun 11, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tvrmb7/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ablynx NV - Alethia Biotherapeutics Inc. - Amgen Inc. - Amura Holdings Ltd. - Bayer AG - ChemoCentryx, Inc. - Debiopharm International S.A. - Deciphera Pharmaceuticals, LLC - Digna Biotech, S.L. - Medivir AB - Merrion Pharmaceuticals Plc - Osteologix Holdings Plc. - R-Pharm - Sigma-Tau S.p.A. For more information visit http://www.researchandmarkets.com/research/tv...metastasis
CCXI: 8.60 (+0.19), AMGN: 154.10 (+2.79)

Post Menopausal Osteoporosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/kgcd25/post_menopausal) has announced the addition of the "Post Menopausal Osteoporosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post Menopausal Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post Menopausal Osteoporosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Merck & Co - Pfizer - Osteologix Holdings - Unigene Laboratories - Radius Health - Chronos Therapeutics - Amgen Astellas BioPharma - Paras Biopharmaceuticals Finland For more information visit http://www.researchandmarkets.com/research/kg...menopausal
RDUS: 72.61 (+2.58), MRK: 57.95 (+0.57), AMGN: 154.10 (+2.79)

Bone Metastasis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 31 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/t39trm/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Eli Lilly and Company - Takeda Pharmaceutical Company Limited - Sigma-Tau S.p.A. - Bayer AG - Medivir AB - Osteologix Holdings Plc. - Transgene SA - Merrion Pharmaceuticals Plc - Digna Biotech, S.L. - Debiopharm International S.A. - Amura Holdings Ltd. - Alethia Biotherapeutics Inc. - Deciphera Pharmaceuticals, LLC - Terpenoid Therapeutics, Inc. - R-Pharm - TWi Pharmaceuticals, Inc. - DexTech Medical AB - AlphaMab Co., Ltd Drug Profiles - denosumab - zoledronic acid - MLN-1202 - radium Ra 223 dichloride - Osteodex - MIV-711 - RPH-203 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Vicrostatin - ADM-01 - LY-2109761 - LY-364937 - Drugs to Inhibit EGFR for Bone Metastasis - (alendronate sodium paclitaxel PEG) - alendronate sodium HPMA paclitaxel - DCC-3014 - Small Molecules to Inhibit GGDPS for Cancer and Bone Metastasis - TPH-9 - NBS-101 - Recombinant Protein to Inhibit Serine Protease for Bone Metastasis For more information visit http://www.researchandmarkets.com/research/t3...metastasis
AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sacrifice Unending: 9/11's Lingering Health Toll

The Unseen Toll of 9/11 on the Firefighter Community Two and a half decades since that fateful morning of September 11, 2001, we're staring at a grim reality. The heroic souls of the New York City Fire Department (FDNY)—those who ran toward peril when others ran away—are still paying the price. Incredibly, more than 400 FDNY members have succumbed to World Trade...

Fresh Thyme Empowers Local Brands in Michigan Debut

A Community-Driven Retail Innovation The grocery game just got a little more personal in Michigan, and we're not talking about run-of-the-mill retail pitches. Fresh Thyme Market, known for its commitment to local and natural products, is shaking things up with their Pitch Thyme Competition. This ain’t your usual product presentation. It’s a whole new ball game where...

ABC Honors 2026 Spirit of the Heart Leaders

Celebrating Champions of Cardiovascular Health In a world where accolades often feel as cold as the stock market after a crash, it’s heartening to see genuine recognition for those who are making actual, lasting impact. On October 3, 2026, the Association of Black Cardiologists (ABC) will hold its annual Spirit of the Heart Awards at none other than Cipriani Wall...

ZEEKR's Shooting Brakes Dominate: Over 400K Sold

ZEEKR's Stellar Performance in a Crowded Market Another month, another bumper crop for ZEEKR's shooting brakes. These beauties aren't just hanging in there; they're leading the pack. In August alone, global deliveries marched past the 10,000 mark for the third month running—a feat not easily achieved in today's saturated automotive landscape. It's no wonder the...

Global Communication Works Opens SignlLabs™ AI Licensing

AI Signaling Moves Beyond GCW's Own Clients Remember when we first looked at GCW's SignlLabs and the idea of helping brands show up inside ChatGPT, Gemini, Claude, Copilot and Perplexity? Well, Global Communication Works is taking the next step. Instead of keeping its AI Signaling playbook inside the agency walls, GCW is now opening SignlLabs up for licensing

Are FULC, WEAV, TECH Shareholders Getting a Raw Deal?

Pocketing Insider Gains Amidst Shareholder Concerns Let me tell you, it smells like another day in the financial jungle where insiders might be feasting while the regular Joe shareholders are left nibbling on crumbs. Fulcrum Therapeutics, Weave Communications, and Bio-Techne are in the crosshairs for deals that may favor those on the inside track over you and me, the...

South Florida Donor Network Honors 52 Heroic Donors

A Heartfelt Tribute to Lifesavers You ever been to a gathering that reminds you how deeply human connections run? That's what happened at The Diplomat Beach Resort in Hollywood. South Florida Donor Network (SFDN) pulled together a ceremony honoring 52 donor heroes whose legacies beat strong through the recipients living thanks to their gifts. An Event Worth Attending...

Push Notification Security Transforms Healthcare IT Support

Cutting the Fat on IT Help Desk Bottlenecks Healthcare IT teams are fighting an uphill battle with password resets, a mundane task consuming up to half of all help desk calls. It's like trying to stop a leaking dam with duct tape. For health systems, these calls aren't just a minor annoyance—they're a full-fledged budget hog. Try telling a CIO that an agent-friendly...

Woodpack Global Unveils Crate Design System: A New Era Begins

Innovating the Wooden Crate Landscape An old industry got a much-needed facelift today, folks. Woodpack Global has rolled out Crate Design System™ (CDS)—a snazzy new tool that's shaking up the wooden crate design landscape. It blows the dust off outdated design methods that have been collecting cobwebs since the '60s. That's right, we’re talking about a significant...

Sandbox VR Expands to Melbourne, Betting on Immersive Fun

Sandbox VR Ventures into Melbourne's Heart Every now and then, a venture takes its ambitions and rolls the dice on a prime location. Sandbox VR is swaggering into Melbourne's bustling Central Business District, fresh out of its success on the Gold Coast. Opening this Melbourne venue on September 14 marks a significant leap in the company's Aussie expansion—a bold nod to...